Navigation Links
GlycoVaxyn AG secures CHF 5.1 million Strategic Translation Award from the Wellcome Trust to finance clinical development of Shigella vaccine
Date:7/29/2013

ZURICH-SCHLIEREN, Switzerland, July 29, 2013 /PRNewswire/ -- Following recently signed collaborations with GlaxoSmithKline Biologicals (GSK) and Janssen Pharmaceuticals (JPI), GlycoVaxyn AG, a leader in the development of innovative conjugate vaccines, today announced that it has secured a Strategic Translation Award from the Wellcome Trust to finance its Shigella program.

The award will allow the Company to advance its Shigella bioconjugate vaccine by funding human safety and challenge studies in healthy adults to confirm the efficacy of a monovalent Shigella flexneri 2a vaccine, before testing a multivalent vaccine in field studies in children. Clinical trials are scheduled to start in 2014 in the USA.

Shigella is one of the main causes of a diarrheal disease that causes illness and death among young children in low-income countries. Various serotypes of this Gram-negative bacterium are responsible for the diarrhea and, with regional differences in serotype distribution, up to 6 serotypes need to be included in a vaccine to provide broad protection and prevent Shigellosis worldwide.

GlycoVaxyn's in vivo glycosylation technology enables the possibility to develop such a complex multivalent Shigella vaccine for the first time. Complexes of the antigenic surface polysaccharides and proteins can now be directly synthesized in genetically engineered bacterial cells. This multivalent Shigella bioconjugate vaccine can be manufactured at low costs, a distinct advantage compared to conjugate vaccines that are chemically produced.

"An estimated 1.1 million people die from Shigella infections each year, mostly children
'/>"/>

SOURCE GlycoVaxyn AG
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. GlycoVaxyn AG announces Addition of Gerd Zettlmeissl, as Chairman of the Board of Directors
2. Modern Mobility Aids, Inc. Secures Financing to Close Acquisition Agreement of LumiGene Technologies
3. A New Type of Dendritic Cell-Based Cancer Vaccine has Received Approval for Clinical Tests and at the Same Time Secures Substantial Financing
4. Roka Bioscience Secures $47.5 Million in Series D Financing
5. Generex Secures Commitments for $3.6M Capital Raise
6. PharmAthene Secures $7.5 Million Credit Facility From GE Capital, Healthcare Financial Services
7. Insmed Secures $20 Million Loan Agreement With Hercules Technology Growth Capital
8. Bacterin Secures $25 Million Financing with OrbiMed
9. OncoSec Secures License for Electroporation Intellectual Property from University of South Florida
10. Aviir Diagnostic Laboratories Secures $8 Million In Funding From Silicon Valley Bank
11. Syngenta Secures EU Approval For Next Generation Fungicide
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... and Annapolis Junction, MD (PRWEB) July 28, 2014 ... research leader in personalized medicine, will be exhibiting data ... at this year’s International Spine Intervention Society’s ... place July 30th-August 3rd, at the Hyatt Regency, in ... to enhance the knowledge and clinical competence of physicians ...
(Date:7/28/2014)... TORONTO , July 28, 2014 /PRNewswire/ -   ... latest group of companies to join its growing portfolio ... hallmarks of Toronto,s JOLT accelerator, ... startups on the roster. Since its ... that have successfully raised  $7.5M of financing. Now at ...
(Date:7/28/2014)... 28, 2014  David Hardison, Ph.D., vice president ... , has been elected chairman of the board ... non-profit working to establish common protocols around the ... relates to electronic health records. ... collaborating with organizations across the research and health ...
(Date:7/28/2014)...   Propeller Health , the FDA-cleared digital health ... Brad Towle as Senior Vice President, Business ... the company,s sales growth, customer acquisition and program expansion. ... his past role in the development of accountable care ... pivotal time in the industry," said David Van ...
Breaking Biology Technology:Proove Biosciences Exhibits Industry Leading Data and Research at International Spine Intervention Society’s 22nd Annual Scientific Meeting 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 2JOLT Announces the Next 6 Startups to Join its Summer 2014 Cohort 3ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 2ConvergeHEALTH by Deloitte's David Hardison Named Chairman of the Clinical Data Interchange Standards Consortium 3Propeller Health Hires Brad Towle as Senior Vice President of Business and Client Development 2
... Hefty has seen blue-ribbon government panels come and go ... thick file of reports spanning 20 years of commissions, ... thoughtful research papers is only useful if it leads ... Hefty, who retired last year from Blue-Cross/Blue Shield United ...
... Role in Community...promotes entertainment everywhere on any device ... approval for the sale of the companys desktop products ... (SPD) The transaction is now complete and Sony Pictures ... it will keep the companys employee base in Madison ...
... alternative energy , ,Madison, WI - WE Energies ... two developers that will build three wind farms increasing ... by 400%. , ,Under the agreement, the two developers, ... LLC, based in Chicago, will provide their entire energy ...
Cached Biology Technology:Governors Growth Council hopes to go light on paperwork and heavy on ideas 2Governors Growth Council hopes to go light on paperwork and heavy on ideas 3Sony Completes Acquisition of Sonic Foundry 2Sony Completes Acquisition of Sonic Foundry 3WE Energies Is Not Letting Wind Power Blow Away 2
(Date:7/28/2014)... and other forms of dementia, but the research community ... of Washington bioengineers have a designed a peptide structure ... normal proteins into a state that,s linked to widespread ... diabetes and Lou Gehrig,s disease. The synthetic molecule blocks ... into an abnormally folded form by targeting a toxic ...
(Date:7/28/2014)... research has identified areas of the Earth that are ... change. , Europe is particularly vulnerable, as it has ... per cent, of any continent in ,refugia, areas ... environmental conditions remain relatively constant during times of great ... are mostly in Scandinavia and Scotland. , The ...
(Date:7/28/2014)... St. Jude Children,s Research Hospital study found that 73 ... doubled their risk of developing metabolic syndrome and related ... The results appear in the current issue of the ... the 1,598 adult survivors of childhood cancer in the ... risk factors like high blood pressure, abdominal obesity, elevated ...
Breaking Biology News(10 mins):New protein structure could help treat Alzheimer's, related diseases 2New protein structure could help treat Alzheimer's, related diseases 3Study finds Europe's habitat and wildlife is vulnerable to climate change 2Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 2Unhealthy habits more than double risk of metabolic syndrome in childhood cancer survivors 3
... comparing the immune responses of both, young and old ... of macrophages, one of the major cell populations involved ... aged mice. This decline in the number of fighters ... be responsible for the age-associated increase in susceptibility to ...
... 2010 Burnham Institute for Medical Research (Burnham) announced ... million to support and further expand and accelerate the ... been renamed the Sanford-Burnham Medical Research Institute. This is ... 2007, he directed $20 million through Sanford Health to ...
... FAIRFAX, Va.Nearly 5,300 physicians, scientists and allied health ... Interventional Radiology,s 35th Annual Scientific Meeting March 13󈝾 ... are scheduled for 9󈝶:30 a.m. on both Monday, ... Annual Scientific Meeting offers ...
Cached Biology News:Rejuvenating the old immune system 2T. Denny Sanford donates $50 million to Burnham Institute for Medical Research 2Press registration open for Society of Interventional Radiology’s 35th Annual Scientific Meeting 2
GeneRacer is an advanced RACE (rapid amplification of cDNA ends) technique that improves the efficiency of amplifying full-length 5' and 3' cDNA ends. With the GeneRacer Kit you can:...
One-step, microplate or cuvet, colorimetric, detection range 0.04% to 4%. Procedure: 30 min....
... 26] to Presenilin 2 Alzheimer's disease ... the disease carry mutations in the presenilin ... protein (APP). These disease-linked mutations result in ... amyloid-beta (main component of amyloid deposits found ...
One-step, microplate or cuvet, colorimetric, linear detection range 0.7 mg/dL to 35 mg/dL. Procedure: 5 min....
Biology Products: